Clinical Trials Logo

Uterine Serous Carcinoma clinical trials

View clinical trials related to Uterine Serous Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06369155 Not yet recruiting - Uterine Cancer Clinical Trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Start date: September 2024
Phase: Phase 2
Study type: Interventional

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT04814108 Recruiting - Clinical trials for Uterine Serous Carcinoma

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Start date: July 28, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

NCT ID: NCT04590248 Completed - Clinical trials for Uterine Serous Carcinoma

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

ADAGIO
Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

NCT ID: NCT04080284 Recruiting - Endometrial Cancer Clinical Trials

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Start date: December 30, 2019
Phase: Phase 2
Study type: Interventional

Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Niraparib maintenance will be a well-tolerated treatment and show significant response in patients with uterine serous carcinoma.